Becker's Healthcare June 14, 2024
Ashleigh Hollowell

The FDA is now advising manufacturers to develop the 2024-2025 COVID-19 vaccines using the KP.2 strain for the formula, the agency announced June 13.

The update comes just one week after an FDA committee voted unanimously June 5 on the 2024-2025 COVID-19 vaccine makeup, recommending it should be one that targets the monovalent JN.1-lineage.

Following the June 5 vote, the committee further discussed if a specific strain from that lineage should be considered for the new vaccines to target, which is what led to this slight change in direction for manufacturers.

KP.2 is part of the JN.1 lineage, but the specification to use the KP.2 strain resulted from current data, which shows that the current...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Pharma / Biotech, Public Health / COVID
Related Articles:
STAT+: Trump’s FDA director pick has a history of criticizing the agency. Here are seven examples
Trump names nominees to lead CDC, FDA, and his pick for surgeon general
Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose
New FDA Panel Weighs In on Regulating Generative AI in Healthcare
Johns Hopkins surgeon Makary is Trump’s pick to lead FDA

Share This Article